GSK2118436 (dabrafenib) with and without the oral MEK1/2 inhibitor GSK1120212 (trametinib)
Channel: Oncoletter
Date: 2012-09-29

Dr. Georgina Long, Melanoma Institute Australia and Westmead Hospital, University of Vienna, ESMO 2012, Pressconference September 29:  Sydney, North Sydney/AUSTRALIA: Phase II randomised study of the oral BRAF inhibitor GSK2118436 (dabrafenib) with and without the oral MEK1/2 inhibitor GSK1120212 (trametinib) in patients with BRAF V600 mutation-positive metastatic melanoma